Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Jiankangyuan ranks among the "Top 500 Guangdong Enterprises", leading industrial upgrading through innovation

Published Time:

2023-10-30

On October 25, the Guangdong Provincial Federation of Enterprises and the Guangdong Provincial Entrepreneurs Association jointly held the 2023 Guangdong Top 500 Enterprises Development Conference, themed "Strengthening Leading Enterprises and Promoting Industrial Upgrading," and solemnly announced the 2023 "Guangdong Top 500 Enterprises" series rankings. HealthGen, based on its comprehensive strength, once again ranked among the "Guangdong Top 500 Enterprises," and also ranked 81st in the "Top 100 Guangdong Private Enterprises" and 65th in the "Top 100 Guangdong Manufacturing Enterprises." 。
The selection of the Guangdong Top 500 Enterprises list mainly uses the enterprises' production and operation indicators as the main selection criteria and is widely regarded as an authoritative list for evaluating the development status of Guangdong enterprises. Data shows that the overall scale of the Guangdong Top 500 enterprises continues to grow, the entry threshold has reached a new level, operating income has achieved a new breakthrough, and the "billion-yuan club" continues to expand, demonstrating strong resilience and growth potential.
HealthGen's inclusion in these three lists is not only a high recognition of its long-term commitment to high-quality development and continuous improvement of its core competitiveness, but also an award for its leading role in promoting Guangdong's economic development and industrial upgrading.
It is worth noting that the R&D expenditure of the 2023 Guangdong Top 500 enterprises reached 4,710.40 billion yuan, a year-on-year increase of 16.03%, and the average R&D expenditure per enterprise was 9.42 billion yuan. Emphasis on research and development and innovation has become the driving force for the continued development of Guangdong enterprises. After decades of development, HealthGen has grown into a comprehensive pharmaceutical enterprise covering multiple fields, including chemical preparations, biological products, chemical raw materials and intermediates, traditional Chinese medicine preparations, diagnostic reagents and equipment, and health food. Relying on solid innovation and R&D capabilities and diversified strategic layout, it has established market competitiveness in multiple pharmaceutical segments.
HealthGen focuses on meeting unmet medical needs through advanced technology and implements a comprehensive strategy that includes independent research and development and external cooperation. The company's business areas are extensive, and through in-depth research and technological innovation, it has established a competitive advantage in multiple disease treatment areas, particularly in respiratory, immuno-oncology, and mental health, where it has a clear R&D roadmap.
While continuously strengthening independent innovation, HealthGen continues to deepen the cooperative development and licensing introduction of core varieties in key areas, connecting with global advantageous resources and cutting-edge technologies, and strengthening the company's commercialization and integration capabilities. In the first half of 2023, HealthGen made phased progress in BD, introducing multiple innovative drugs and continuously expanding other indications in the respiratory system, accelerating the company's transformation into an innovative pharmaceutical company. Among them, TG-1000 is an innovative PA endonuclease inhibitor that can effectively inhibit both influenza A and B viruses. It has completed Phase II clinical trials, and Phase III clinical trials are underway. XYP-001 is an improved innovative drug for the treatment of idiopathic pulmonary fibrosis (IPF), and Phase I clinical trials are currently underway, with clinical research continuing to progress.
HealthGen plans to further strengthen its independent R&D system, continue to deepen the "innovative drugs + high-barrier complex preparations" dual-drive strategy around several core medical fields, accelerate the R&D progress of key products such as TG-1000 and XYP-001, and seek opportunities for technological and product layout globally. Through external cooperation, it will further enrich its product line to achieve its long-term sustainable development.
Shenzhen, as China's most successful economic special zone, has attracted a large number of high-growth, high-tech, and high-potential industry-leading enterprises like HealthGen. The excellent business environment empowers private enterprises, releasing even greater development momentum and creativity. Based in Shenzhen and looking at the world, HealthGen will continue to play a demonstration and leading role, adhering to innovation as its guide, carefully developing new drugs, improving its overall competitiveness and status in the industry, and contributing to China's medical and health cause.